Rapid Evolution of the Neutralizing Antibody Response to HIV Type 1 Infection

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2003 Mar 20

PMID 12644702

Citations 653

Authors

Douglas D Richman

Terri Wrin

Susan J Little

Christos J Petropoulos

Affiliations

Soon will be listed here.

Abstract

A recombinant virus assay was used to characterize in detail neutralizing antibody responses directed at circulating autologous HIV in plasma. Examining serial plasma specimens in a matrix format, most patients with primary HIV infection rapidly generated significant neutralizing antibody responses to early (0-39 months) autologous viruses, whereas responses to laboratory and heterologous primary strains were often lower and delayed. Plasma virus continually and rapidly evolved to escape neutralization, indicating that neutralizing antibody exerts a level of selective pressure that has been underappreciated based on earlier, less comprehensive characterizations. These data argue that neutralizing antibody responses account for the extensive variation in the envelope gene that is observed in the early months after primary HIV infection.

Citing Articles

Assessing bnAb potency in the context of HIV-1 envelope conformational plasticity.

Foulkes C, Friedrich N, Ivan B, Stiegeler E, Magnus C, Schmidt D PLoS Pathog. 2025; 21(1):e1012825.

PMID: 39836706 PMC: 11774494. DOI: 10.1371/journal.ppat.1012825.

Current methods for detecting and assessing HIV-1 antibody resistance.

Odidika S, Pirkl M, Lengauer T, Schommers P Front Immunol. 2025; 15():1443377.

PMID: 39835119 PMC: 11743526. DOI: 10.3389/fimmu.2024.1443377.

Functional variability of Nef in antagonizing SERINC5 during acute to chronic HIV-1 infection.

Li W, Li G, Liu Y, Meng L, Zhang T, Wang L AIDS. 2024; 39(3):229-240.

PMID: 39612239 PMC: 11784911. DOI: 10.1097/QAD.0000000000004079.

Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial.

Carpp L, Hyrien O, Fong Y, Benkeser D, Roels S, Stieh D Nat Commun. 2024; 15(1):9785.

PMID: 39532861 PMC: 11557889. DOI: 10.1038/s41467-024-53727-y.

HIV-1 diversity in viral reservoirs obtained from circulating T-cell subsets during early ART and beyond.

Zhang Y, Otte F, Stoeckle M, Thielen A, Daumer M, Kaiser R PLoS Pathog. 2024; 20(9):e1012526.

PMID: 39292732 PMC: 11410260. DOI: 10.1371/journal.ppat.1012526.

References

Wrin T, Crawford L, Sawyer L, Weber P, Sheppard H, Hanson C . Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr (1988). 1994; 7(3):211-9. View

Burns D, Collignon C, Desrosiers R . Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J Virol. 1993; 67(7):4104-13. PMC: 237779. DOI: 10.1128/JVI.67.7.4104-4113.1993. View

Moore J, Cao Y, Ho D, Koup R . Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol. 1994; 68(8):5142-55. PMC: 236458. DOI: 10.1128/JVI.68.8.5142-5155.1994. View

Wei X, Ghosh S, Taylor M, Johnson V, Emini E, Deutsch P . Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995; 373(6510):117-22. DOI: 10.1038/373117a0. View

Trkola A, Pomales A, Yuan H, Korber B, Maddon P, Allaway G . Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol. 1995; 69(11):6609-17. PMC: 189569. DOI: 10.1128/JVI.69.11.6609-6617.1995. View

Connick E, Marr D, Zhang X, Clark S, Saag M, Schooley R . HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res Hum Retroviruses. 1996; 12(12):1129-40. DOI: 10.1089/aid.1996.12.1129. View

Havlir D, Eastman S, Gamst A, Richman D . Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol. 1996; 70(11):7894-9. PMC: 190861. DOI: 10.1128/JVI.70.11.7894-7899.1996. View

DSouza M, Livnat D, Bradac J, Bridges S . Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working.... J Infect Dis. 1997; 175(5):1056-62. DOI: 10.1086/516443. View

Kessler 2nd J, McKenna P, Emini E, Chan C, Patel M, Gupta S . Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses. 1997; 13(7):575-82. DOI: 10.1089/aid.1997.13.575. View

10.

Perelson A, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K . Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997; 387(6629):188-91. DOI: 10.1038/387188a0. View

11.

Burton D . A vaccine for HIV type 1: the antibody perspective. Proc Natl Acad Sci U S A. 1997; 94(19):10018-23. PMC: 33768. DOI: 10.1073/pnas.94.19.10018. View

12.

Wyatt R, Kwong P, DESJARDINS E, Sweet R, Robinson J, Hendrickson W . The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 1998; 393(6686):705-11. DOI: 10.1038/31514. View

13.

Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W . Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med. 1999; 5(2):204-10. DOI: 10.1038/5568. View

14.

Schmitz J, Kuroda M, Santra S, Sasseville V, Simon M, Lifton M . Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999; 283(5403):857-60. DOI: 10.1126/science.283.5403.857. View

15.

Jin X, Bauer D, Tuttleton S, Lewin S, Gettie A, Blanchard J . Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med. 1999; 189(6):991-8. PMC: 2193038. DOI: 10.1084/jem.189.6.991. View

16.

Bradney A, Scheer S, Crawford J, Buchbinder S, Montefiori D . Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. J Infect Dis. 1999; 179(5):1264-7. DOI: 10.1086/314711. View

17.

Mascola J, Lewis M, Stiegler G, Harris D, Vancott T, Hayes D . Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999; 73(5):4009-18. PMC: 104180. DOI: 10.1128/JVI.73.5.4009-4018.1999. View

18.

Little S, McLean A, Spina C, Richman D, Havlir D . Viral dynamics of acute HIV-1 infection. J Exp Med. 1999; 190(6):841-50. PMC: 2195636. DOI: 10.1084/jem.190.6.841. View

19.

Parren P, Moore J, Burton D, Sattentau Q . The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity. AIDS. 2000; 13 Suppl A:S137-62. View

20.

Parren P, Burton D . The antiviral activity of antibodies in vitro and in vivo. Adv Immunol. 2001; 77:195-262. PMC: 7131048. DOI: 10.1016/s0065-2776(01)77018-6. View